Steen-Olsen Emma Balch, Pappot Helle, Green Allan, Langberg Henning, Holländer-Mieritz Cecilie
Department of Oncology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen Ø, Denmark.
Knowledge Center of Telemedicine, Region Hovedstaden, Hillerød, Denmark.
JMIR Res Protoc. 2022 Oct 3;11(10):e37626. doi: 10.2196/37626.
Studies have shown that there may be dissimilar perceptions on symptoms or side effects between patients with cancer and health care professionals. This may lead to symptomatic patients notifying the clinic irregularly or not telling the clinic at all. Wearables could help identify symptoms earlier. Patients with low socioeconomic status and less self-awareness of their health may benefit from this. A new design of wearables is a smart t-shirt that, with embedded sensors, provides measurement flows such as electrocardiogram, thoracic and abdominal respiration, and temperature.
This study evaluates the feasibility of using a smart t-shirt for home monitoring of biometric sensor data in adolescent and young adult and elderly patients during cancer treatment.
The OncoSmartShirt study is an explorative study investigating the feasibility of using the Chronolife smart t-shirt during cancer treatment. This smart t-shirt is designed with multiple fully embedded sensors and electrodes that engender 6 different measurement flows continuously. A total of 20 Danish patients with cancer ≥18 years old in antineoplastic treatment at Department of Oncology Rigshospitalet Denmark will be recruited from all cancer wards, whether patients are in curative or palliative care. Of these 20 patients, 10 (50%) will be <39 years old, defined as adolescent and young adult, and 10 (50%) will be patients >65 years old, defined as elderly. Consenting patients will be asked to wear a smart t-shirt daily for 2 weeks during their treatment course.
The primary outcome is to determine if it is feasible to wear a smart t-shirt throughout the day (preferably 8 hours per day) for 2 weeks. Inclusion of patients started in March 2022.
The study will assess the feasibility of using the Chronolife smart t-shirt for home monitoring of vital parameters in patients with cancer during their treatment and bring new insights into how wearables and biometric data can be used as part of symptom or side-effect recognition in patients with cancer during treatment, with the aim to increase patients' quality of life.
ClinicalTrials.gov NCT05235594; https://beta.clinicaltrials.gov/study/NCT05235594.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/37626.
研究表明，癌症患者与医护人员对症状或副作用的认知可能存在差异。这可能导致有症状的患者不定期通知诊所或根本不告知诊所。可穿戴设备有助于更早地识别症状。社会经济地位较低且健康自我意识较差的患者可能会从中受益。一种新设计的可穿戴设备是智能T恤，它嵌入了传感器，可提供心电图、胸腹部呼吸和体温等测量数据。
本研究评估在癌症治疗期间，使用智能T恤对青少年、年轻成年人及老年患者的生物特征传感器数据进行家庭监测的可行性。
OncoSmartShirt研究是一项探索性研究，旨在调查在癌症治疗期间使用Chronolife智能T恤的可行性。这款智能T恤设计有多个完全嵌入式传感器和电极，可连续产生6种不同的测量数据。丹麦哥本哈根大学医院肿瘤内科正在接受抗肿瘤治疗的20名年龄≥18岁的丹麦癌症患者将从所有癌症病房招募，无论患者是接受根治性治疗还是姑息治疗。在这20名患者中，10名（50%）年龄<39岁，定义为青少年和年轻成年人，10名（50%）年龄>65岁，定义为老年人。同意参与的患者将被要求在治疗期间每天穿着智能T恤2周。
主要结果是确定在2周内每天（最好每天8小时）穿着智能T恤是否可行。患者纳入工作于2022年3月开始。
该研究将评估使用Chronolife智能T恤对癌症患者治疗期间的生命体征参数进行家庭监测的可行性，并为可穿戴设备和生物特征数据如何作为癌症患者治疗期间症状或副作用识别的一部分提供新的见解，旨在提高患者的生活质量。
ClinicalTrials.gov NCT05235594；https://beta.clinicaltrials.gov/study/NCT05235594。
国际注册报告识别码（IRRID）：PRR1-10.2196/37626。
